Novavax Dirección

Dirección controles de criterios 1/4

El CEO de Novavax es John Jacobs , nombrado en Jan 2023, tiene una permanencia de 1.83 años. compensación anual total es $7.30M, compuesta por 9.1% salario y 90.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.03% de las acciones de la empresa, por valor de €386.57K. La antigüedad media del equipo directivo y de la junta directiva es de 1.8 años y 4.3 años, respectivamente.

Información clave

John Jacobs

Chief Executive Officer (CEO)

US$7.3m

Compensación total

Porcentaje del salario del CEO	9.1%
Permanencia del CEO	1.8yrs
Participación del CEO	0.03%
Permanencia media de la dirección	1.8yrs
Promedio de permanencia en la Junta Directiva	4.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de John Jacobs en comparación con los beneficios de Novavax?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$285m
Jun 30 2024	n/a	n/a	-US$294m
Mar 31 2024	n/a	n/a	-US$399m
Dec 31 2023	US$7m	US$663k	-US$545m

Compensación vs. Mercado: La compensación total de John($USD7.30M) está por encima de la media de empresas de tamaño similar en el mercado BG ($USD1.45M).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de John con los resultados de la empresa.

CEO

John Jacobs (57 yo)

1.8yrs

Permanencia

US$7,301,009

Compensación

Mr. John Charles Jacobs, M.B.A., serves as Chief Executive Officer and Director of Novavax, Inc. since January 23, 2023 and serves as its President from January 23, 2023. He was Director of Life Sciences P...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
John Jacobs	President	1.8yrs	US$7.30m	0.030% € 386.6k
John Trizzino	President & COO	less than a year	US$1.88m	0.018% € 230.2k
James Kelly	Executive VP	3.3yrs	US$1.50m	0.0090% € 117.4k
Mark Casey	Executive VP	less than a year	US$1.53m	sin datos
Richard Crowley	Executive VP & COO	1.8yrs	sin datos	sin datos
Troy Morgan	Senior VP	no data	sin datos	sin datos
Erika Trahan	Associate Director of Investor & Public Relations	6.6yrs	sin datos	sin datos
Ian Watkins	Executive VP & Chief Human Resources Officer	1.3yrs	sin datos	sin datos
Silvia Taylor	Executive VP and Chief Corporate Affairs & Advocacy Officer	2.8yrs	sin datos	sin datos
Robert Walker	Senior VP & Chief Medical Officer	no data	sin datos	sin datos
Elaine O'Hara	Executive VP & Chief Strategy Officer	1.8yrs	sin datos	0.0089% € 115.7k
Ruxandra Draghia-Akli	EVP and Head of Research & Development	no data	sin datos	sin datos

1.8yrs

Permanencia media

59.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de NVV1 no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
John Jacobs	President	1.8yrs	US$7.30m	0.030% € 386.6k
David Mott	Independent Director	4.4yrs	US$187.53k	0.032% € 410.5k
Richard Douglas	Independent Director	14.8yrs	US$189.53k	0.027% € 357.3k
Margaret McGlynn	Independent Director	3.9yrs	US$185.02k	0.0065% € 85.2k
Gregg Alton	Independent Director	4.1yrs	US$175.28k	0.0065% € 85.2k
Rachel King	Independent Director	6yrs	US$174.55k	0.012% € 153.9k
Richard Rodgers	Independent Director	2.1yrs	US$191.78k	0.0065% € 85.2k
James Young	Independent Chairman of the Board	14.6yrs	US$222.53k	0.039% € 502.4k

4.3yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de NVV1 se considera experimentada (4.3 años de antigüedad promedio).

Novavax Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Novavax, Inc. Notifies Retirement of Filip Dubovsky as President, Research and Development, Effective as of June 30, 2024

President of Research & Development recently sold €355k worth of stock

Novavax, Inc., Annual General Meeting, Jun 13, 2024

Novavax, Inc. Announces Changes to Executive Leadership Team

High number of new directors

Novavax, Inc. Announces Chief Executive Officer Changes

Recent updates

Third quarter 2024 earnings released: US$0.76 loss per share (vs US$1.26 loss in 3Q 2023)

Novavax, Inc. Revises Revenue Guidance for the Full Year 2024

U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

Novavax, Inc Announces Update on Covid-19-Influenza Combination and Stand-Alone Influenza Phase 3 Trial

Forecast breakeven date pushed back to 2026

Novavax, Inc. Updated 2024-2025 Nuvaxovid™ Covid-19 Vaccine Receives Authorization in the EU

Forecast breakeven date moved forward to 2025

Novavax Announces Availability of Updated Covid-19 Vaccine with Emergency Use Authorization from FDA

Novavax Announces That Novavax COVID-19 Vaccine, Adjuvanted Receives Emergency Use Authorization from the U.S. Food and Drug Administration

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

New major risk - Shareholder dilution

Second quarter 2024 earnings released: EPS: US$1.09 (vs US$0.65 in 2Q 2023)

Novavax, Inc. Revises Revenue Guidance for the Full Year 2024

Novavax, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Novavax, Inc. Submits Application to U.S. FDA for Updated Protein-Based 2024-2025 Formula COVID-19 Vaccine

Novavax, Inc. Notifies Retirement of Filip Dubovsky as President, Research and Development, Effective as of June 30, 2024

President of Research & Development recently sold €355k worth of stock

New major risk - Financial position

Novavax, Inc. Revises Revenue Guidance for the Full Year 2024

First quarter 2024 earnings released: US$1.06 loss per share (vs US$3.41 loss in 1Q 2023)

No longer forecast to breakeven

Novavax, Inc. to Report Q1, 2024 Results on May 10, 2024

Novavax, Inc., Annual General Meeting, Jun 13, 2024

New minor risk - Profitability

No longer forecast to breakeven

Forecast breakeven date moved forward to 2025

Novavax, Inc. Provides Earnings Guidance for First Quarter and Full Year 2024

Novavax, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Forecast to breakeven in 2026

Forecast breakeven date pushed back to 2026

Novavax, Inc. Announces The Taiwan Food and Drug Administration Grants Emergency Use Authorization for Nuvaxovid™ XBB.1.5 Dispersion for Injection Covid-19 Vaccine (Recombinant, Adjuvanted) (NVX-CoV2601) for Active Immunization to Prevent Covid-19 in Individuals Aged 12 and Older

Novavax, Inc. Announces Changes to Executive Leadership Team

Novavax, Inc. Provides Earnings Guidance for the First Quarter of 2024

No longer forecast to breakeven

Novavax, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Novavax's Updates Nuvaxovid COVID-19 Vaccine Receives Positive CHMP Opinion in the EU

New minor risk - Profitability

Forecast to breakeven in 2024

Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid™ in United Kingdom

Novavax, Inc. Announces Updated Protein-Based XBB Covid Vaccine Induced Neutralizing Responses Against Emerging Subvariants

Novavax, Inc. announced that it expects to receive $84.5 million in funding from SK bioscience Co.,Ltd.

Novavax, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New minor risk - Profitability

No longer forecast to breakeven

Novavax's Nuvaxovid™? Receives Full Marketing Authorization in the Eu for the Prevention of Covid

Novavax, Inc.(NasdaqGS:NVAX) dropped from Russell Midcap Index

Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU

No longer forecast to breakeven

Novavax, Inc. Provides Earnings Guidance for the Full Year 2023

High number of new directors

Novavax, Inc. announced that it has received $6.75 million in funding from River Private Wealth

Novavax, Inc. Announces Chief Executive Officer Changes

Novavax, Inc. Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates

Novavax, Inc. has completed a Follow-on Equity Offering in the amount of $65 million.

No longer forecast to breakeven

Novavax, Inc. has completed a Follow-on Equity Offering in the amount of $65 million.

Novavax, Inc. Reaffirms Revenue Guidance for the Full Year 2022

Novavax, Inc. Appoints Richard J. Rodgers as Member of Its Audit Committee and as A Member of Its Compensation Committee

Novavax, Inc. Announces Nuvaxovid COVID-19 Vaccine Approval in Canada for Use as a Primary Series in Adolescents

No longer forecast to breakeven

Novavax, Inc. Announces the World Health Organization Issue an Updated Emergency Use Listing (EUL) for Nuvaxovid(TM) (NVX-CoV2373) COVID-19

Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults

Third quarter 2022 earnings released: US$2.15 loss per share (vs US$4.31 loss in 3Q 2021)

Novavax, Inc. Announces Medicines and Healthcare Products Regulatory Agency Expands Conditional Marketing Authorization for Nuvaxovid™ COVID-19 Vaccine

Novavax, Inc. Revises Revenue Guidance for the Year 2022

Novavax, Inc. to Report Q3, 2022 Results on Nov 08, 2022

U.S. FDA Grants Emergency Use Authorization for Novavax, Inc.'s COVID-19 Vaccine, Adjuvanted as a Booster for Adults

Novavax, Inc. Announces Positive Results from Phase 1/2 Clinical Trial of Its COVID-19-Influenza Combination (CIC) Vaccine Candidate